Partial
Mostly Aligned
Patient Risk:
Low
Summary
The AI claims largely extend beyond the labeled use of magnesium sulfate (IV for preeclampsia/eclampsia) and include general dietary/supplement guidance not present in the label. Some statements align with label warnings (renal impairment risk, pregnancy/nursing considerations, and certain drug interactions), but many others are not supported by the FDA label.
Category Scores
Accurate Statements
People with kidney disease face higher hypermagnesemia risk, as impaired kidneys can't excrete excess.
WARNINGS; CLINICAL PHARMACOLOGY
Pregnant or breastfeeding individuals need medical advice.
Pregnancy; Nursing Mothers
A serum magnesium level of 6 mg/100 mL is considered optimal for control of seizures.
DOSAGE AND ADMINISTRATION
In severe renal insufficiency, the maximum dosage of magnesium sulfate is 20 g per 48 hours.
DOSAGE AND ADMINISTRATION
Unsupported Statements
Magnesium supplements can interact with certain blood pressure drugs, potentially lowering blood pressure too much or causing other effects.
Label does not discuss antihypertensive interactions; label lists interactions with aminoglycosides, amphotericin B, diuretics, digitalis, cisplatin, alcohol.
It's generally safe for many people at moderate doses (under 350 mg daily from supplements), but risks rise with specific meds, high doses, or kidney issues.
No labeled tolerable upper intake or general supplement safety; not specific to the IV obstetric indication.
Always check with a doctor before combining, as individual factors like dosage and health conditions matter.
Label does not explicitly mandate pre-use physician consultation for all combinations; pregnancy/nursing contexts recommend professional guidance.
Calcium channel blockers (e.g., amlodipine, diltiazem) pose the biggest risk—magnesium enhances their effects, leading to excessive blood pressure drops, dizziness, or irregular heartbeat.
No label reference to antihypertensive interactions or magnified effects with calcium channel blockers.
Loop diuretics (e.g., furosemide) and thiazide diuretics (e.g., hydrochlorothiazide) deplete magnesium levels, so supplements might help restore balance but require monitoring to avoid hypermagnesemia.
Label notes drug-induced renal losses and monitoring in renal impairment, but does not advocate supplementation to balance magnesium.
ACE inhibitors (e.g., lisinopril) and ARBs (e.g., losartan) have fewer direct interactions, though high magnesium can amplify blood pressure reduction.
No label reference to these interactions.
Beta-blockers (e.g., metoprolol) rarely interact significantly.
No labeled interaction data for beta-blockers.
Common issues include hypotension (low blood pressure), fatigue, nausea, or muscle weakness, especially if total magnesium exceeds 400 mg daily.
Label does not provide these general adverse effects or a 400 mg daily threshold for supplements.
People with kidney disease face higher hypermagnesemia risk, as impaired kidneys can't excrete excess.
This claim is already captured as an accurate statement.
Rare severe effects: heart rhythm changes or breathing problems at very high doses (>5g).
Label does not specify >5 g; toxicity potential exists but the exact threshold is not defined in the label.
Studies show no major issues in short-term use for most healthy adults, but long-term data is limited.
Not present in label.
Stick to the RDA: 310-420 mg daily from food and supplements combined.
Not present in label.
Food sources (nuts, spinach, beans) are safest with minimal interaction risk.
Not present in label.
Supplements: 200-350 mg elemental magnesium (e.g., citrate or glycinate forms absorb best).
Not present in label.
Split doses to avoid GI upset.
Not present in label.
Blood tests can monitor levels—aim for 0.75-0.95 mmol/L serum magnesium.
Target ranges provided in label are not this range; monitoring is addressed but numbers differ.
Skip if you have kidney failure, myasthenia gravis, or take drugs like antibiotics (gentamicin) alongside BP meds, as interactions compound.
Kidney impairment and aminoglycoside interactions exist in label; BP-med interactions are not described.
Stop 2 weeks before surgery due to blood pressure effects.
Perioperative withholding guidance is not in the label.
A 2021 meta-analysis found magnesium supplementation safely lowers blood pressure by 2-3 mmHg in hypertensives, sometimes used adjunctively with meds.
Not present in label.
American Heart Association notes potential benefits but warns of interactions with antihypertensives.
Not present in label.
NIH advises consulting providers for those on prescriptions.
Not present in label.
Contradictions
Important Omissions
The AI does not address the label's approved indication (management of preeclampsia/eclampsia) or the specific IV administration details and fetal safety warnings beyond brief mentions.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The claims largely center on general magnesium interactions and safety; many are not supported by the label, but there are a few label-aligned safety points (renal impairment risk, pregnancy/nursing cautions). No explicit dangerous misguidance identified in the AI claims themselves.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several claimed interactions and dosing guidance are not supported by the label; need to limit to label-supported information.
Suggested Improvement
Restrict statements to label-supported interactions (aminoglycosides, diuretics, digitalis, cisplatin, alcohol), indications (pre-eclampsia/eclampsia), and pregnancy/nursing considerations; avoid extrapolated 'RDA' or antihypertensive interaction claims.